“Plug-and-Play” CAR T Platform Enables Post-Infusion Retargeting

Meditope-enabled CAR T cells can be tracked, selectively expanded, and directed toward additional tumor antigens using externally administered protein adaptors

September 23, 2026
3 min

The Medicine Maker

1

The modular CAR T-cell platform allows post-infusion modification of engineered immune cells' behavior and targeting.
2

The meCAR developed at City of Hope features a docking site for protein adaptors, enhancing CAR T-cell functionality.
3

In preclinical studies, meCAR T cells showed comparable tumor-cell killing to conventional CAR T cells.
4

Combining adaptors with meCAR T cells improved T-cell expansion and reduced tumor burden in mouse models.
5

The platform's flexibility allows for the addition of new capabilities to CAR T cells as needed, but dosing must be optimized.

“Plug-and-Play” CAR T Platform Enables Post-Infusion Retargeting

1

2

3

4

5

Original Source(s)

“Plug-and-Play” CAR T Platform Enables Post-Infusion Retargeting

Related Content

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge

Safety-Oriented Benchmarking of Large Language Models in Risk-Based Management of Abnormal Cervical Screening Results: Scenario-Based Benchmark Study